A health perspective of hormonal contraceptives.
Fraser
I S
IS
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000230:Adenocarcinoma / Q000453:epidemiology; D000328:Adult; D000367:Age Factors; D000814:Aniline Compounds / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003271:Contraceptive Agents, Female / Q000009:adverse effects; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008599:Menstruation Disturbances / Q000139:chemically induced; D009369:Neoplasms / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000453:epidemiology; D000292:Pelvic Inflammatory Disease / Q000453:epidemiology; D011247:Pregnancy; D012306:Risk; D012449:Safety; D014594:Uterine Neoplasms / Q000453:epidemiology
D000814:Aniline Compounds; D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; C050795:N,N-dimethyl-4-anisidine